VIENNA--A new study from the EORTC Gynecologic Cancer Cooperative Group
(GCCG) has challenged the assumption that aggressive combination chemotherapy
is worthwhile in chemotherapy-naïve women with metastatic squamous
cell cancer of the cervix.
Although a highly active four-drug combination yielded a response rate
superior to that seen with cisplatin alone, it resulted in substantially
greater hematologic and nonhematologic toxicity, and afforded no survival
advantage, Dr. Jan Vermorken of Amsterdam's Free University Hospital, said
at the European Society for Medical Oncology Congress.
The study documented a 31% response rate in the 143 women assigned to
BEMP (bleomycin, vindesine, mitomycin C, cisplatin) versus 19% in the 144
This benefit was achieved at the cost of more frequent complications,
treatment delays, and dose reductions. At 6 years' follow-up, survival
curves for the two regimens were superimposable.